Aplitabart - IGM Biosciences
Alternative Names: IGM-8444Latest Information Update: 22 Aug 2024
Price :
$50 *
At a glance
- Originator IGM Biosciences
- Class Antibodies; Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action TRAIL receptor 2 agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Colorectal cancer; Non-Hodgkin's lymphoma; Solid tumours
- Suspended Acute myeloid leukaemia
Most Recent Events
- 14 Aug 2024 IGM Biosciences completes enrollment in phase I trial in Colorectal cancer (Late-stage disease, Metastatic disease, Monotherapy, Combination therapy, Second-line therapy or greater) in the US, Asia and Europe (IV)
- 05 Apr 2024 Pharmacodynamics data from preclinical trials in Solid tumours presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 05 Dec 2023 Suspended - Phase-I for Acute myeloid leukaemia (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Australia (IV)